Skip to main content
. 2016 Jun 1;15(8):2641–2670. doi: 10.1074/mcp.M115.057794

Fig. 10.

Fig. 10.

BBB studies at 0, 1, 3, 7, 10, 14, 21, and 28 days in following experimental groups: in sham, following SCI, and after SCI + anti-CD20 antibody injection. Note, no significant differences in motor function recovery between SCI and SCI+ anti-CD20 treatment during survival.